0000899243-19-001178.txt : 20190115 0000899243-19-001178.hdr.sgml : 20190115 20190115100116 ACCESSION NUMBER: 0000899243-19-001178 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181116 FILED AS OF DATE: 20190115 DATE AS OF CHANGE: 20190115 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vexler Vladimir CENTRAL INDEX KEY: 0001759506 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36721 FILM NUMBER: 19526366 MAIL ADDRESS: STREET 1: 333 TWIN DOLPHIN DRIVE STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Coherus BioSciences, Inc. CENTRAL INDEX KEY: 0001512762 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273615821 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 649-3530 MAIL ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: BioGenerics, Inc. DATE OF NAME CHANGE: 20110210 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2018-11-16 2018-11-20 0 0001512762 Coherus BioSciences, Inc. CHRS 0001759506 Vexler Vladimir COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY CA 94065 0 1 0 0 Chief Scientific Officer Common Stock, $0.0001 par value 7828 D Stock Option (right to buy) 2.0838 2023-02-28 Common Stock 71982 D Stock Option (right to buy) 29.00 2025-04-01 Common Stock 25000 D Stock Option (right to buy) 14.43 2026-02-26 Common Stock 25000 D Stock Option (right to buy) 17.17 2026-05-11 Common Stock 24618 D Stock Option (right to buy) 20.15 2027-04-03 Common Stock 25000 D Stock Option (right to buy) 12.70 2027-08-06 Common Stock 50000 D Stock Option (right to buy) 9.30 2027-11-15 Common Stock 25000 D Stock Option (right to buy) 10.05 2028-02-01 Common Stock 75000 D This Form 3 amendment has been filed solely to correct the amount of securities beneficially owned as shown in Table I, column 2 of both the original Form 3 and the Form 3A. The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Jean Frederic Viret, as Attorney-in-Fact for Vladimir Vexler 2019-01-15